Effective airway clearance remains a cornerstone of management for patients with chronic mucus retention, including those with cystic fibrosis (CF), non–CF bronchiectasis, neuromuscular disease, and chronic obstructive pulmonary disease (COPD) with a chronic bronchitis phenotype1. Persistent mucus retention contributes to airway obstruction, infection risk, and chronic inflammation, leading to recurrent exacerbations and progressive functional decline. High-frequency chest wall oscillation (HFCWO) has become an established, guideline-supported airway clearance therapy, particularly for patients who struggle with effort-dependent techniques or require consistent long-term treatment. Over time, device design has emerged as a key determinant of real-world effectiveness. Newer wearable HFCWO systems, such as the AffloVest, aim to address practical limitations that have historically interfered with adherence to traditional pneumatic vest therapies2.
HFCWO delivers externally generated oscillatory forces to the chest wall, which are transmitted to the lung parenchyma and conducting airways3. These high-frequency oscillations create rapid, cyclical changes in pleural pressure and airflow velocity. Together, these forces facilitate mucus mobilization through several interrelated mechanisms. Oscillatory shear stress reduces mucus viscosity and elasticity, making secretions easier to displace along airway surfaces. At the same time, transient increases in expiratory airflow promote an expiratory flow bias that favors cephalad movement of secretions toward central airways, where they can be expectorated or suctioned4.
Unlike techniques that rely on patient-generated forced expiratory maneuvers, HFCWO operates independently of patient coordination or respiratory muscle strength5. This distinction is clinically important. In conditions such as CF, bronchiectasis, and advanced COPD, where airflow limitation, fatigue, or dyspnea may compromise active airway clearance, HFCWO provides a consistent and reproducible physiologic stimulus. In neuromuscular disorders, where cough effectiveness is often severely impaired, externally driven oscillation can mobilize secretions without imposing additional respiratory workload on the patient6.
Experimental and clinical studies have demonstrated that oscillatory airflow enhances bulk mucus transport even when mucociliary clearance is dysfunctional. As a result, HFCWO supports airway clearance across multiple lung regions simultaneously, rather than relying on localized postural techniques or patient-directed maneuvers alone.
A substantial and growing body of literature supports the use of HFCWO across several chronic pulmonary disease states7-9. In cystic fibrosis, randomized crossover trials comparing HFCWO with conventional chest physiotherapy have consistently shown comparable outcomes with respect to sputum expectoration, pulmonary function, and exacerbation frequency. Importantly, these studies also highlighted advantages related to patient independence and ease of long-term use – factors that are increasingly recognized as critical to sustained treatment effectiveness in chronic disease.
Evidence supporting HFCWO has expanded beyond CF. In non–CF bronchiectasis, observational and registry-based studies demonstrate clinically meaningful benefits, particularly in patients with frequent exacerbations or high daily sputum burden10. A large longitudinal cohort study reported reductions in respiratory-related hospitalizations and antibiotic use following initiation of HFCWO, compared with patients’ pre-treatment baselines11. These findings suggest that, in selected patients, improved secretion clearance may translate into tangible reductions in healthcare utilization.
In COPD, especially among patients with chronic bronchitis phenotypes characterized by daily sputum production, HFCWO has been studied primarily as an adjunctive therapy. Systematic reviews and meta-analyses indicate that HFCWO increases sputum expectoration and may shorten hospital length of stay during acute exacerbations, although effects on spirometric outcomes are variable12. This variability likely reflects heterogeneity in disease severity, treatment protocols, and outcome measures rather than a lack of physiologic effect. Quality-of-life improvements, including reductions in dyspnea and symptom burden, have been reported in several studies, reinforcing the relevance of patient-centered outcomes in this population.
HFCWO has also demonstrated utility in patients with neuromuscular disease, where ineffective cough and secretion retention are major contributors to morbidity. In these populations, HFCWO is often incorporated into multimodal airway clearance regimens and has been shown to improve secretion mobilization without increasing respiratory fatigue. Across disease states, adherence consistently emerges as a key moderator of clinical benefit. Device usability, comfort, and integration into daily life strongly influence whether the physiologic advantages of HFCWO are realized in practice.
Despite established efficacy, traditional HFCWO systems present practical challenges13. Conventional devices rely on external air-pulse generators connected to inflatable vests via large-bore tubing. This configuration restricts patient mobility during therapy sessions and typically requires dedicated time spent tethered to stationary equipment. For many patients, particularly those who are working, caregiving, or managing multiple chronic conditions, these constraints interfere with consistent use. Over time, treatment burden, setup complexity, and vest bulk may contribute to declining adherence, even when patients recognize symptomatic benefit.
The AffloVest represents an evolution in HFCWO technology designed to mitigate many of these limitations. Rather than using pneumatic air pulses, the device incorporates integrated oscillatory modules distributed across the thorax. This design eliminates the need for external hoses or compressors and allows the system to operate as a fully wearable, battery-powered device.
From a clinical perspective, portability has meaningful implications. Patients can ambulate, perform light activities, or incorporate therapy into daily routines rather than scheduling prolonged, sedentary treatment sessions. This flexibility may be particularly valuable for individuals with competing functional demands or a history of suboptimal adherence to airway clearance therapy. In such cases, reduced disruption to daily life may increase consistency of use and, by extension, therapeutic benefit.
The segmented oscillation pattern also allows for more targeted chest wall stimulation. Improved fit and reduced bulk may enhance comfort, especially for smaller adults, adolescents transitioning to adult care, or patients with musculoskeletal limitations who find traditional vests difficult to tolerate. Importantly, these design innovations preserve the fundamental physiologic mechanism of HFCWO while reducing treatment burden, aligning with contemporary emphases on patient-centered chronic disease management.
As with all airway clearance modalities, HFCWO (and wearable systems such as the AffloVest) should be prescribed based on individualized clinical assessment. Patients with chronic daily sputum production, recurrent exacerbations, or limited ability to perform active airway clearance techniques are most likely to benefit. Wearable HFCWO may be especially advantageous when nonadherence is driven by logistical or lifestyle barriers rather than physiologic limitations.
HFCWO is typically most effective when integrated into a multimodal regimen that includes bronchodilators, mucolytics, and directed cough techniques. Thoughtful sequencing of therapies, patient education, and periodic reassessment of clinical response remain essential to optimizing outcomes.
High-frequency chest wall oscillation is a well-established, evidence-based airway clearance therapy with demonstrated physiologic and clinical benefits across a range of chronic pulmonary conditions. While traditional pneumatic systems remain effective, innovations in device design have important implications for adherence and patient experience. Wearable, hose-free systems such as the AffloVest maintain the therapeutic integrity of HFCWO while reducing treatment burden. For pulmonologists seeking to optimize long-term airway clearance outcomes, balancing physiologic efficacy with real-world usability is essential, and newer wearable HFCWO technologies represent a meaningful advance in achieving that balance.
1. Button, Brenda M, and Brian Button. “Structure and function of the mucus clearance system of the lung.” Cold Spring Harbor perspectives in medicine vol. 3,8 a009720. 1 Aug. 2013, doi:10.1101/cshperspect.a009720
2. Leemans, Glenn et al. “The effectiveness of a mobile high-frequency chest wall oscillation (HFCWO) device for airway clearance.” Pediatric pulmonology vol. 55,8 (2020): 1984-1992. doi:10.1002/ppul.24784
3. Mahajan, Amit K et al. “High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial.” Respiratory research vol. 12,1 120. 10 Sep. 2011, doi:10.1186/1465-9921-12-120
4. Volpe, Marcia S et al. “Ventilation patterns influence airway secretion movement.” Respiratory care vol. 53,10 (2008): 1287-94.
5. Morrison, Lisa, and Stephanie Innes. “Oscillating devices for airway clearance in people with cystic fibrosis.” The Cochrane database of systematic reviews vol. 5,5 CD006842. 4 May. 2017, doi:10.1002/14651858.CD006842.pub4
6. Gipsman, Alexander Ilan et al. “Airway clearance in patients with neuromuscular disease.” Paediatric respiratory reviews vol. 47 (2023): 33-40. doi:10.1016/j.prrv.2023.02.002
7. Mari, Pier-Valerio et al. “Focused Pulse High-frequency Chest Wall Oscillation (FP-HFCWO) for Mucus Management in COPD (Chronic Obstructive Pulmonary Disease) and Asthma: A Single-center Cohort Study.” The open respiratory medicine journal vol. 19 e18743064391693. 3 Jul. 2025, doi:10.2174/0118743064391693250627115047
8. Urribarri, Martha E. Camacho, Brian C. Becker, and Angela C. Murray. "Impact of High-Frequency Chest Wall Oscillation on Health Care Resource Use and Economic Outcomes in Adult Patients With Non-Cystic Fibrosis Bronchiectasis in the United States: A Pre-Post Cohort Analysis." CHEST Pulmonary 2.1 (2024): 100013.
9. Ge, Jiaqi, et al. "High-frequency chest wall oscillation multiple times daily can better reduce the loss of pulmonary surfactant and improve lung compliance in mechanically ventilated patients." Heart & Lung 61 (2023): 114-119.
10. Imam, Jaafer Saadi, and Alexander G. Duarte. "Non-CF bronchiectasis: orphan disease no longer." Respiratory medicine 166 (2020): 105940.
11. Barto, Tara Lynn et al. “Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis.” Therapeutic advances in respiratory disease vol. 14 (2020): 1753466620932508. doi:10.1177/1753466620932508
12. Huang, Hsiao-Ping et al. “Effects of High-Frequency Chest Wall Oscillation on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” International journal of chronic obstructive pulmonary disease vol. 17 2857-2869. 10 Nov. 2022, doi:10.2147/COPD.S378642